Atypical teratoid/rhabdoid tumor, usually called ATRT, is one of the most aggressive cancers that can form in the brain or spinal cord. It predominantly strikes very young children, often before age three, and accounts for a meaningful share of brain tumors diagnosed in infancy. The defining feature of ATRT is not what the tumor gains but what it loses: a single gene mutation disables a critical cellular switch, and that alone is enough to drive malignancy. Treatment has improved considerably over the past two decades, but ATRT remains difficult to cure and carries a high risk of lasting harm to survivors.
What Makes ATRT Different From Other Brain Tumors
Under the microscope, ATRT is striking for its variety. The tumor can contain the classic “rhabdoid” cells that give it part of its name, along with small round blue cells, and regions that look like they are trying to become muscle, skin, or nerve tissue. This mix of cell appearances, called polyphenotypic differentiation, initially led pathologists to confuse ATRT with other childhood brain tumors such as medulloblastoma or primitive neuroectodermal tumors. For years, many ATRTs were misclassified, which muddied survival data and delayed development of targeted treatments.1PubMed Central. Atypical teratoid/rhabdoid tumors: challenges and search for solutions
The breakthrough in diagnosis came when researchers discovered that virtually all ATRTs share one molecular signature: loss of expression of a protein called SMARCB1 (also known as INI1). A standard lab test for this protein is now the cornerstone of diagnosis. If a childhood brain tumor shows the chaotic appearance of ATRT and the SMARCB1 protein is absent on staining, the diagnosis is essentially confirmed.2PubMed Central. Atypical teratoid/rhabdoid tumors: challenges and search for solutions
The Genetic Root of the Disease
ATRT is genetically one of the simplest cancers known. Most cancers accumulate dozens or hundreds of gene mutations over time. ATRT typically has just one that matters: biallelic inactivation of the SMARCB1 gene. Both copies of the gene must be knocked out. SMARCB1 encodes a component of a large molecular machine called the SWI/SNF chromatin-remodeling complex, which controls how tightly DNA is wound around its structural proteins. When SWI/SNF works properly, it opens or closes specific stretches of DNA so that genes can be switched on or off at the right time during development. Without a functioning SMARCB1 protein, this regulation goes haywire, and immature cells keep dividing instead of maturing into their intended tissue types.3Cancer Cell. Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation
A small fraction of ATRTs involve a different gene in the same complex, called SMARCA4. These SMARCA4-mutated tumors appear to form a separate biological group. They tend to occur at an even younger age, carry a higher rate of inherited (germline) mutations, and have a worse prognosis than SMARCB1-mutated cases. Their molecular profile is distinct enough that researchers consider them a separate subgroup rather than just a variation on the same theme.4PubMed Central. Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases
Molecular Subtypes and Why They Matter
Beyond the SMARCB1-versus-SMARCA4 split, researchers have identified three main molecular subgroups of SMARCB1-mutated ATRTs based on their DNA methylation patterns: ATRT-TYR, ATRT-SHH, and ATRT-MYC. These names refer to the signaling pathways that are most active in each subgroup.5PubMed Central. Molecular subgrouping of atypical teratoid/rhabdoid tumors—a reinvestigation and current consensus Each subgroup tends to appear in different locations in the brain, at slightly different ages, and with different microscopic appearances.6PubMed Central. Histopathological patterns in atypical teratoid/rhabdoid tumors are related to molecular subgroup
The SHH subgroup itself may split further. Imaging and molecular studies have found that SHH ATRTs can be divided into two distinct sub-subgroups with different gene expression profiles and specific anatomic locations, suggesting these tumors arise from different types of developing brain cells.7Nature Communications. Imaging and multi-omics datasets converge to define different neural progenitor origins for ATRT-SHH subgroups This kind of granularity matters because it opens the door to subtype-specific treatment strategies. A drug that works for ATRT-MYC may do nothing for ATRT-TYR, and trials are increasingly being designed with molecular subgroup in mind.
How ATRT Shows Up Clinically
Because ATRT usually appears in children under three, its symptoms depend heavily on where the tumor grows and how old the child is. Infants cannot describe a headache or blurry vision, so the first red flags are often indirect: a bulging soft spot on the skull, vomiting that seems unrelated to feeding, unusual eye movements, or a head that is growing faster than expected. Older toddlers may become irritable, lose coordination, or stop reaching developmental milestones.
On MRI, ATRTs tend to be large at the time of diagnosis, averaging roughly four centimeters across. They frequently show areas of bleeding, dead tissue, and calcium deposits, and they light up strongly with contrast dye. Perhaps most concerning, nearly half of patients already have signs that the tumor has spread through the fluid around the brain and spinal cord at the time they are first diagnosed.8PubMed. Imaging findings in primary intracranial atypical teratoid/rhabdoid tumors That tendency to spread early is one of the features that makes ATRT so difficult to control. Even after treatment achieves an initial response, recurrence with widespread spread along the brain and spine lining is a common pattern.9PubMed. Imaging findings in primary intracranial atypical teratoid/rhabdoid tumors
Rarer presentations do occur. Some ATRTs arise along specific cranial nerves, such as the nerve that controls eye movement, presenting initially as a drooping eyelid or a fixed pupil in an infant.10PubMed Central. Atypical Teratoid/Rhabdoid Tumor (ATRT) Arising from the 3rd Cranial Nerve in Infants: A Clinical-Radiological Entity? Others spread diffusely across the brain’s lining without forming a clear mass, which can delay diagnosis because the imaging does not show the typical single tumor.11PubMed Central. Primary diffuse leptomeningeal atypical teratoid rhabdoid tumor (AT/RT) demonstrating atypical imaging findings in an adolescent patient
Rhabdoid Tumor Predisposition Syndrome
About a third of ATRT patients carry a germline alteration in SMARCB1, meaning the mutation is present in every cell in their body, not just in the tumor.12Neuro-Oncology. ATRT-21. Contribution of germline mosaic alterations of SMARCB1 in rhabdoid tumor predisposition syndrome This defines a condition called rhabdoid tumor predisposition syndrome (RTPS). Children with RTPS carry a greatly increased risk of developing ATRT within the first two years of life, and the prognosis in these cases tends to be poor.13Neuro-Oncology Advances. SDPS-18 RHABDOID TUMOR PREDISPOSITION SYNDROME IN TWO INFANT SIBLINGS WITH ATYPICAL TERATOID RHABDOID TUMORS DUE TO A GERMLINE SMARCB1 MUTATION These children are also at risk for rhabdoid tumors arising outside the brain, particularly in the kidneys.
Because RTPS can run in families, siblings of a child diagnosed with ATRT should be evaluated. Genetic counseling is standard practice after an ATRT diagnosis to determine whether the mutation was inherited or arose spontaneously. Some germline mutations involve mosaicism, where only a fraction of a parent’s cells carry the mutation, making detection trickier but no less important for family planning and surveillance.
Surgery, Radiation, and Chemotherapy
The backbone of ATRT treatment is aggressive multimodal therapy: surgery to remove as much tumor as possible, followed by some combination of radiation and chemotherapy. The extent of surgical removal has a large impact on survival. In one institutional review, roughly two-thirds of patients who had a complete tumor removal were alive at follow-up, compared to about 29% of those with a near-total removal and just 12.5% of those with only a partial removal. Age at surgery and whether the disease had already spread were also strong predictors of outcome.14PubMed. Outcomes with respect to extent of surgical resection for pediatric atypical teratoid rhabdoid tumors
A pooled analysis of hundreds of patients found that when children could tolerate the full treatment package, including complete surgical removal, radiation therapy, and intensive chemotherapy with intrathecal delivery (injected into the spinal fluid), the five-year overall survival reached about 88%.15PubMed. Overall Survival of Primary Intracranial Atypical Teratoid Rhabdoid Tumor Following Multimodal Treatment: A Pooled Analysis of Individual Patient Data That number represents the best-case scenario, though. Many young children cannot safely receive the full regimen, especially radiation therapy, which poses serious risks to the developing brain.
The Radiation Dilemma in Very Young Children
Radiation is one of the most effective weapons against ATRT, but delivering it to the brain of a one-year-old is a brutal tradeoff. The developing brain is exquisitely sensitive to radiation, and treatment can cause lasting cognitive harm, growth problems, and hormonal deficits. For years, some treatment centers tried to avoid or delay radiation by using intensive chemotherapy alone, including high-dose chemotherapy with autologous stem cell rescue. The results were disappointing. One study evaluating tandem rounds of high-dose chemotherapy with stem cell support in young children found that disease progressed early in most patients, and the strategy did not succeed as a substitute for radiation.16Cancer Research and Treatment. Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Atypical Teratoid/Rhabdoid Tumor Only a small proportion of patients could be cured with this approach.17PubMed Central. High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system
Proton beam radiation has become an important tool for managing this tradeoff. Unlike traditional X-ray-based radiation, proton beams can be shaped to deposit most of their energy directly in the tumor and spare more of the surrounding healthy brain. Early clinical experience with proton therapy in ATRT has been encouraging: in one series, nine out of ten patients were alive without disease at last follow-up, and proton delivery spared significantly more of the cerebrum, temporal lobes, hearing structures, and hypothalamus than would have been possible with conventional photon radiation.18PubMed. Early clinical outcomes using proton radiation for children with central nervous system atypical teratoid rhabdoid tumors A comparison on a major cooperative registry found that tumor control was equivalent between proton and photon therapy, with no detectable advantage for either modality in terms of disease outcome, but the tissue-sparing profile of protons may translate into fewer long-term side effects.19PubMed Central. ATRT-10. EARLY POST RADIATION CHANGES AND EFFICACY IN CHILDREN WITH ATRT TREATED ON COG ACNS 0333: A COMPARISON OF PROTON VS PHOTON THERAPY
A related question is how much of the brain and spine to irradiate. Some protocols treat only the tumor bed (focal radiation), while others irradiate the entire brain and spine (craniospinal irradiation). A prospective registry analysis found no statistically significant difference in four-year overall survival or event-free survival between focal radiation and craniospinal irradiation among patients without metastatic disease.20PubMed. Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR) This is still an open question, however, because ATRT’s tendency to spread along the brain lining makes the case for broader treatment fields, and the registry numbers were modest enough that real differences could have been missed.
Targeted and Experimental Treatments
ATRT’s genetic simplicity is actually an advantage for drug development. Because the tumor is driven by one core defect, researchers have a clear target. The most advanced targeted approach involves drugs that inhibit an enzyme called EZH2. When SMARCB1 is lost, a rival system controlled in part by EZH2 gains outsized influence over gene activity. Blocking EZH2 aims to restore some balance. In a phase I clinical trial, the EZH2 inhibitor tazemetostat produced a response in about 19% of children with ATRT, with responses lasting a median of six and a half months.21Journal of Clinical Oncology. Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors A 19% response rate is modest, but for a single agent in a tumor type this aggressive, it represents genuine proof of concept.
Laboratory work has shed light on why EZH2 inhibition works when it does. In ATRT cells, blocking EZH2 triggers a cascade: silenced repetitive DNA elements become active, producing double-stranded RNA and stray DNA fragments that the cell’s immune-sensing machinery interprets as evidence of a viral infection. This “viral mimicry” response switches on interferon signaling pathways, turning the tumor cell’s own defenses against itself.22Nature Communications. Inhibiting EZH2 targets atypical teratoid rhabdoid tumor by triggering viral mimicry via both RNA and DNA sensing pathways Understanding this mechanism is opening the door to combination strategies, such as pairing EZH2 inhibitors with immune-activating drugs, that could amplify the effect.
Because ATRT’s mutational burden is low, the tumor tends to develop resistance to any single targeted agent relatively quickly. Researchers increasingly believe that combination therapy, rather than any one drug, will be the key to improving outcomes for relapsed or treatment-resistant disease.23Dove Press (Cancer Management and Research). Current Molecular and Clinical Landscape of ATRT – The Link to Future Therapies
CAR T-cell therapy is another frontier. Engineered immune cells designed to recognize a surface marker called B7-H3, which is found on ATRT cells, have shown strong results in laboratory models. In one preclinical study, these CAR T-cells killed ATRT cells effectively in culture and, when delivered into the brain ventricles of mice carrying ATRT tumors, provided long-term protection against tumor rechallenge.24Neuro-Oncology Practice. Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT) Human clinical trials are in early stages.
Life After ATRT for Survivors
With more children surviving ATRT, the long-term consequences of the tumor and its treatment are coming into sharper focus. The news is sobering. Even among survivors who did not receive radiation, a Canadian registry study found significant cognitive impairment at school age.25PubMed. Neurocognitive evaluation of long term survivors of atypical teratoid rhabdoid tumors (ATRT): The Canadian registry experience The tumor itself, the surgery, and the chemotherapy all contribute to neurodevelopmental harm, independent of radiation.
A German study that assessed survivors of infant ATRT found that the deficits were not evenly distributed across cognitive domains. Fluid intelligence and visual processing were hit hardest, while other areas like language were relatively less affected. Psychomotor speed and attention were also well below normal. Beyond test scores, quality-of-life measures showed impairments in social functioning, school performance, and overall psychosocial health compared to healthy children.26PubMed. Survivors of infant atypical teratoid/rhabdoid tumors present with severely impaired cognitive functions especially for fluid intelligence and visual processing: data from the German brain tumor studies These findings underscore that surviving ATRT is only part of the challenge. Families need long-term neuropsychological follow-up, educational accommodations, and often rehabilitative support to help survivors reach their potential.
ATRT in Adults
While ATRT is overwhelmingly a pediatric disease, it does occur in adults, rarely enough that each case is something of an event at the treating hospital. A compiled analysis of 74 adult cases found a striking female predominance, with women outnumbering men nearly four to one. The most common location in adults is the sellar region near the pituitary gland, which is different from the posterior fossa distribution that predominates in children. Median overall survival in adults was about 12.5 months. Chemotherapy was the only treatment factor independently associated with longer survival, and the best outcomes were seen in patients who received surgery plus both chemotherapy and radiation.27PubMed. Atypical teratoid/rhabdoid tumor in adult: case series and an integrated survival analysis
Autologous stem cell transplantation has been explored in a handful of adult cases. While data are extremely limited, a review of five adult patients who underwent this procedure found that all survived longer than the historical average, and four had no evidence of disease at their last follow-up.28PubMed Central. Autologous stem cell transplantation in adults with atypical teratoid rhabdoid tumor: a case report and review Five patients is far too few to draw conclusions, but in a disease with a median survival of roughly one year in adults, the observation is worth tracking as more cases accumulate.
When Families Face a Palliative Path
Not every child diagnosed with ATRT is a candidate for the aggressive treatment described above. Infants diagnosed in the first year of life face the harshest odds. A Canadian registry review found that nearly half of these youngest patients were directed to palliative care rather than curative-intent treatment, compared to about 11% of similar cases in the broader published literature. The palliated infants were significantly younger, with a median age of about three months versus almost seven months for those who received active therapy. For these families, the medical conversation shifts from cure rates and treatment protocols to comfort, time at home, and support. The gap between the youngest diagnosed patients and those old enough to tolerate intensive therapy represents one of the starkest inequalities in pediatric oncology.